

Kentaro Miyake

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4636289/publications.pdf>

Version: 2024-02-01

166
papers

2,977
citations

159585

30
h-index

254184

43
g-index

170
all docs

170
docs citations

170
times ranked

1809
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of locomotive syndrome in patients receiving surgical treatment for degenerative musculoskeletal diseases: A multicentre prospective study using the new criteria. <i>Modern Rheumatology</i> , 2022, 32, 822-829.	1.8	1
2	Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1096.	4.1	17
3	Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 2393-2405.	1.5	7
4	Pretreatment Neutrophil Count and Platelet-lymphocyte Ratio as Predictors of Metastasis in Patients With Osteosarcoma. <i>Anticancer Research</i> , 2022, 42, 1081-1089.	1.1	7
5	A scoring system combining clinical, radiological, and histopathological examinations for differential diagnosis between lipoma and atypical lipomatous tumor/well-differentiated liposarcoma. <i>Scientific Reports</i> , 2022, 12, 237.	3.3	13
6	Linkage of methionine addiction, histone lysine hypermethylation, and malignancy. <i>IScience</i> , 2022, 25, 104162.	4.1	14
7	Primary total knee arthroplasty assisted by computed tomography-free navigation for secondary knee osteoarthritis following massive calcium phosphate cement packing for distal femoral giant-cell bone tumor treatment: a case report. <i>BMC Musculoskeletal Disorders</i> , 2022, 23, 170.	1.9	0
8	Therapeutic effects and clinical outcomes of immune checkpoint inhibitors on bone metastases in lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21118-e21118.	1.6	0
9	Clinical outcomes and life expectancy of patients with unplanned excisions of soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, e23554-e23554.	1.6	1
10	Compartment-specific clinical outcomes in patients with soft tissue sarcomas of the thigh.. <i>Journal of Clinical Oncology</i> , 2022, 40, e23549-e23549.	1.6	0
11	Novel predictors associated with therapeutic effects of immune checkpoint inhibitors on bone metastasis of non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21071-e21071.	1.6	0
12	Multikinase-Inhibitor Screening in Drug-resistant Osteosarcoma Patient-derived Orthotopic Xenograft Mouse Models Identifies the Clinical Potential of Regorafenib. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 637-643.	2.0	4
13	The number of osteoclasts in a biopsy specimen can predict the efficacy of neoadjuvant chemotherapy for primary osteosarcoma. <i>Scientific Reports</i> , 2021, 11, 1989.	3.3	6
14	Reduction of gender-associated M2-like tumor-associated macrophages in the tumor microenvironment of patients with pancreatic cancer after neoadjuvant chemoradiotherapy. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 174-182.	2.6	12
15	Reconstruction using a frozen autograft for a skull and humeral lesion of synchronous multicentric osteosarcoma after undergoing successful neoadjuvant chemotherapy: a case report and review of the literature. <i>BMC Surgery</i> , 2021, 21, 56.	1.3	4
16	Long-term survival in a patient with Hutchinson-Gilford progeria syndrome and osteosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 854-863.	0.8	0
17	Combination Methionine-methylation-axis Blockade: A Novel Approach to Target the Methionine Addiction of Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 113-120.	2.0	12
18	Significant Improvement After Surgery for a Symptomatic Osteoblastoma in a Patient with Camurati-Engelmann Disease: Case Report and Literature Review. <i>Calcified Tissue International</i> , 2021, 108, 819-824.	3.1	1

#	ARTICLE	IF	CITATIONS
19	An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model. <i>Scientific Reports</i> , 2021, 11, 8583.	3.3	11
20	Delayed Initiation of Treatment Is Associated With Metastasis of Malignant Bone Tumor. <i>Anticancer Research</i> , 2021, 41, 2993-2999.	1.1	3
21	A Radiological Scoring System for Differentiation between Enchondroma and Chondrosarcoma. <i>Cancers</i> , 2021, 13, 3558.	3.7	6
22	Clinical outcomes of frozen autograft reconstruction for the treatment of primary bone sarcoma in adolescents and young adults. <i>Scientific Reports</i> , 2021, 11, 17291.	3.3	8
23	Severe anaphylaxis caused by intravenous anti-cancer drugs. <i>Cancer Medicine</i> , 2021, 10, 7174-7183.	2.8	9
24	Association of low back pain with muscle weakness, decreased mobility function, and malnutrition in older women: A cross-sectional study. <i>PLoS ONE</i> , 2021, 16, e0245879.	2.5	10
25	Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review. <i>Anticancer Research</i> , 2021, 41, 5865-5871.	1.1	13
26	Patient-derived orthotopic xenograft models of sarcoma. <i>Cancer Letters</i> , 2020, 469, 332-339.	7.2	17
27	The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 285-291.	2.3	27
28	Combination of oral recombinant methioninase and decitabine arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma patient-derived orthotopic xenograft mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2020, 523, 135-139.	2.1	15
29	PPAR α Agonist Pioglitazone in Combination With Cisplatin Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 35-40.	2.0	24
30	Secondary Osteoarthritis After Curettage and Calcium Phosphate Cementing for Giant-Cell Tumor of Bone Around the Knee Joint. <i>JBJS Open Access</i> , 2020, 5, e19.00068-e19.00068.	1.5	9
31	Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. <i>Translational Oncology</i> , 2020, 13, 100826.	3.7	6
32	A novel patient-derived orthotopic xenograft (PDOX) mouse model of highly-aggressive liver metastasis for identification of candidate effective drug-combinations. <i>Scientific Reports</i> , 2020, 10, 20105.	3.3	8
33	Diagnosis and treatment of intramedullary osteosclerosis: a report of three cases and literature review. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 762.	1.9	3
34	Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. <i>Cancer Letters</i> , 2020, 492, 174-184.	7.2	21
35	Improvement of locomotive syndrome with surgical treatment in patients with degenerative diseases in the lumbar spine and lower extremities: a prospective cohort study. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 515.	1.9	13
36	Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of malignant bone and soft-tissue tumor involving an epiphysis. <i>Journal of Bone Oncology</i> , 2020, 24, 100310.	2.4	10

#	ARTICLE	IF	CITATIONS
37	Structural Origin and Surgical Complications of Peripheral Schwannomas. <i>Anticancer Research</i> , 2020, 40, 6563-6570.	1.1	1
38	Low-grade myofibroblastic sarcoma of the levator scapulae muscle: a case report and literature review. <i>BMC Musculoskeletal Disorders</i> , 2020, 21, 836.	1.9	10
39	Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice. <i>In Vivo</i> , 2020, 34, 1027-1030.	1.3	0
40	A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatin-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 217-223.	2.0	7
41	Eribulin Regresses a Cisplatin-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2020, 40, 2475-2479.	1.1	7
42	Recombinant Methioninase Combined With Tumor-targeting <i>Salmonella typhimurium</i> A1-R Induced Regression in a PDOX Mouse Model of Doxorubicin-resistant Dedifferentiated Liposarcoma. <i>Anticancer Research</i> , 2020, 40, 2515-2523.	1.1	4
43	Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 351-358.	2.0	3
44	Recent Advances and Challenges in the Treatment of Rhabdomyosarcoma. <i>Cancers</i> , 2020, 12, 1758.	3.7	30
45	Exquisite Tumor Targeting by <i>Salmonella</i> A1-R in Combination with Caffeine and Valproic Acid Regresses an Adult Pleomorphic Rhabdomyosarcoma Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2020, 13, 393-400.	3.7	7
46	The accuracy of different FRAX tools in predicting fracture risk in Japan: A comparison study.. <i>Journal of Orthopaedic Surgery</i> , 2020, 28, 230949902091727.	1.0	4
47	Glycogen synthase kinase β as a potential therapeutic target in synovial sarcoma and fibrosarcoma. <i>Cancer Science</i> , 2020, 111, 429-440.	3.9	28
48	Delayed Initiation of Treatment Is Associated With Metastasis of Soft-tissue Sarcoma. <i>Anticancer Research</i> , 2020, 40, 7009-7015.	1.1	7
49	A case of triple digestive tract reconstruction in chronic pancreatitis complicated with bile ductal stenosis, duodenal stenosis, and portal vein stenosis: a case report. <i>Surgical Case Reports</i> , 2020, 6, 116.	0.6	0
50	Distal Tibial Tuberosity Focal Dome Osteotomy Combined With Intra-Articular Condylar Osteotomy (Focal Dome Condylar Osteotomy) for Medial Osteoarthritis of the Knee Joint. <i>Arthroscopy Techniques</i> , 2020, 9, e1079-e1086.	1.3	3
51	Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Journal of Drug Targeting</i> , 2019, 27, 211-216.	4.4	11
52	Sorafenib and Palbociclib Combination Regresses a Cisplatin-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4079-4084.	1.1	24
53	Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis. <i>Anticancer Research</i> , 2019, 39, 4065-4071.	1.1	6
54	The Combination of Olaratumab with Doxorubicin and Cisplatin Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model. <i>Translational Oncology</i> , 2019, 12, 1257-1263.	3.7	18

#	ARTICLE	IF	CITATIONS
55	Peritoneal Metastases in a Patient-derived Orthotopic Xenograft (PDOX) Model of Colon Cancer Imaged Non-invasively via Red Fluorescent Protein Labeled Stromal Cells. <i>Anticancer Research</i> , 2019, 39, 3463-3467.	1.1	8
56	Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4775-4779.	1.1	16
57	Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatin in a Patient-derived Orthotopic Xenograft Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4667-4671.	1.1	26
58	Esophageal metastasis of breast cancer during endocrine therapy for pleural dissemination 21 years after breast surgery: a case report. <i>Surgical Case Reports</i> , 2019, 5, 22.	0.6	11
59	Pioglitazone, an agonist of PPAR γ , reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression. <i>Biomedicine and Pharmacotherapy</i> , 2019, 118, 109356.	5.6	28
60	Combination Treatment With Sorafenib and Everolimus Regresses a Doxorubicin-resistant Osteosarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2019, 39, 4781-4786.	1.1	22
61	Efficacy of prolonged elemental diet therapy after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: A pilot prospective randomized trial (UMIN00004108). <i>Clinical Nutrition ESPEN</i> , 2019, 34, 116-124.	1.2	4
62	Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. <i>Anticancer Research</i> , 2019, 39, 5339-5344.	1.1	6
63	Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 509, 1041-1046.	2.1	12
64	Efficacy of Recombinant Methioninase (rMETase) on Recalcitrant Cancer Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models: A Review. <i>Cells</i> , 2019, 8, 410.	4.1	35
65	Efficacy of Tumor-Targeting Salmonella typhimurium A1-R against Malignancies in Patient-Derived Orthotopic Xenograft (PDOX) Murine Models. <i>Cells</i> , 2019, 8, 599.	4.1	18
66	The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109093.	5.6	4
67	Pazopanib regresses a doxorubicin-resistant synovial sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 107-111.	2.2	3
68	Determining Patient Satisfaction and Treatment Desires in Patients With Musculoskeletal Sarcoma of the Knee After Joint-preservation Surgery Using a Questionnaire Survey. <i>Anticancer Research</i> , 2019, 39, 1965-1969.	1.1	4
69	Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2019, 58, 17-23.	2.2	10
70	Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. <i>Cancer Letters</i> , 2019, 451, 122-127.	7.2	11
71	Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 809-815.	2.3	16
72	Successful treatment of pathologic femoral shaft fracture associated with large arteriovenous malformations using a 3-dimensional external fixator and teriparatide: a case report. <i>BMC Surgery</i> , 2019, 19, 35.	1.3	10

#	ARTICLE	IF	CITATIONS
73	Satisfaction After Joint-preservation Surgery in Patients With Musculoskeletal Knee Sarcoma Based on Various Scores. <i>Anticancer Research</i> , 2019, 39, 1959-1964.	1.1	3
74	Trabectedin and irinotecan combination regresses a cisplatin-resistant osteosarcoma in a patient-derived orthotopic xenograft nude-mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2019, 513, 326-331.	2.1	34
75	The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 1075-1082.	2.3	7
76	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes nab-paclitaxel resistance in a cervical cancer PDOX mouse model. <i>Archives of Gynecology and Obstetrics</i> , 2019, 299, 1683-1690.	1.7	14
77	Methioninase Cell-Cycle Trap Cancer Chemotherapy. <i>Methods in Molecular Biology</i> , 2019, 1866, 133-148.	0.9	2
78	High Efficacy of Recombinant Methioninase on Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Cancer. <i>Methods in Molecular Biology</i> , 2019, 1866, 149-161.	0.9	6
79	A patient-derived orthotopic xenograft (PDOX) nude-mouse model precisely identifies effective and ineffective therapies for recurrent leiomyosarcoma. <i>Pharmacological Research</i> , 2019, 142, 169-175.	7.1	14
80	Osimertinib Regresses an EGFR-Mutant Cisplatin-Resistant Lung Adenocarcinoma Growing in the Brain in Nude Mice. <i>Translational Oncology</i> , 2019, 12, 640-645.	3.7	10
81	Oral Recombinant Methioninase, Combined With Oral Caffeine and Injected Cisplatin, Overcome Cisplatin-Resistance and Regresses Patient-derived Orthotopic Xenograft Model of Osteosarcoma. <i>Anticancer Research</i> , 2019, 39, 4653-4657.	1.1	30
82	The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2019, 111, 835-840.	5.6	10
83	Detection of Metastasis in a Patient-derived Orthotopic Xenograft (PDOX) Model of Undifferentiated Pleomorphic Sarcoma with Red Fluorescent Protein. <i>Anticancer Research</i> , 2019, 39, 81-85.	1.1	19
84	Therapeutic Targets for Bone and Soft-Tissue Sarcomas. <i>International Journal of Molecular Sciences</i> , 2019, 20, 170.	4.1	52
85	Regorafenib regresses an imatinib-resistant recurrent gastrointestinal stromal tumor (GIST) with a mutation in exons 11 and 17 of c-kit in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Cell Cycle</i> , 2018, 17, 722-727.	2.6	9
86	Tumor-targeting <i>Salmonella typhimurium</i> A1-R is a highly effective general therapeutic for undifferentiated soft tissue sarcoma patient-derived orthotopic xenograft nude-mouse models. <i>Biochemical and Biophysical Research Communications</i> , 2018, 497, 1055-1061.	2.1	28
87	Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer. <i>Cell Cycle</i> , 2018, 17, 868-873.	2.6	23
88	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with recombinant methioninase and cisplatin eradicates an osteosarcoma cisplatin-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic. <i>Cell Cycle</i> , 2018, 17, 801-809.	2.6	57
89	Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. <i>Annals of Surgical Oncology</i> , 2018, 25, 1079-1085.	1.5	40
90	Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. <i>Cell Cycle</i> , 2018, 17, 627-633.	2.6	13

#	ARTICLE	IF	CITATIONS
91	Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma. <i>Cancer Letters</i> , 2018, 417, 168-173.	7.2	56
92	Tumor-targeting <i>Salmonella typhimurium</i> A1-R Promotes Tumoricidal CD8 ⁺ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic Cancer Orthotopic Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 634-639.	2.6	23
93	Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 967-972.	2.6	13
94	Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention. <i>Cell Cycle</i> , 2018, 17, 356-361.	2.6	40
95	Growth of doxorubicin-resistant undifferentiated spindle cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 3537-3544.	2.6	30
96	Combining Tumor-Selective Bacterial Therapy with <i>Salmonella typhimurium</i> A1-R and Cancer Metabolism Targeting with Oral Recombinant Methioninase Regressed an Ewing's Sarcoma in a Patient-Derived Orthotopic Xenograft Model. <i>Chemotherapy</i> , 2018, 63, 278-283.	1.6	25
97	Metabolic targeting with recombinant methioninase combined with palbociclib regresses a doxorubicin-resistant dedifferentiated liposarcoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 506, 912-917.	2.1	29
98	Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model. <i>Anticancer Research</i> , 2018, 38, 5639-5644.	1.1	50
99	A combination of irinotecan/cisplatin and irinotecan/temozolomide or tumor-targeting <i>Salmonella typhimurium</i> A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model. <i>Biochemical and Biophysical Research Communications</i> , 2018, 505, 733-739.	2.1	18
100	Tumor-targeting <i>Salmonella typhimurium</i> A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). <i>Tissue and Cell</i> , 2018, 54, 144-149.	2.2	8
101	The usefulness of wide excision assisted by a computer navigation system and reconstruction using a frozen bone autograft for malignant acetabular bone tumors: a report of two cases. <i>BMC Cancer</i> , 2018, 18, 1036.	2.6	11
102	Combination therapy of tumor-targeting <i>Salmonella typhimurium</i> A1-R and oral recombinant methioninase regresses a BRAF-V600E-negative melanoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 3086-3092.	2.1	27
103	MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. <i>Tissue and Cell</i> , 2018, 52, 124-128.	2.2	19
104	Tumor-targeting <i>Salmonella typhimurium</i> A1-R arrests a doxorubicin-resistant PDGFRA-amplified patient-derived orthotopic xenograft mouse model of pleomorphic liposarcoma. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 7827-7833.	2.6	6
105	Tumor targeting <i>Salmonella typhimurium</i> A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopic xenograft (PDOX) nude mouse models. <i>Cell Cycle</i> , 2018, 17, 2019-2026.	2.6	18
106	Patient-derived orthotopic xenograft models for cancer of unknown primary precisely distinguish chemotherapy, and tumor-targeting <i>S. typhimurium</i> A1-R is superior to first-line chemotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 12.	17.1	5
107	Temozolomide regresses a doxorubicin-resistant undifferentiated spindle cell sarcoma patient-derived orthotopic xenograft (PDOX): precision oncology nude mouse model matching the patient with effective therapy. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 6598-6603.	2.6	14
108	Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model. <i>Tissue and Cell</i> , 2018, 53, 30-36.	2.2	18

#	ARTICLE	IF	CITATIONS
109	Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model. <i>BMC Cancer</i> , 2018, 18, 840.	2.6	14
110	Tumor-targeting <i>Salmonella typhimurium</i> A1-R suppressed an imatinib-resistant gastrointestinal stromal tumor with c-kit exon 11 and 17 mutations. <i>Heliyon</i> , 2018, 4, e00643.	3.2	11
111	Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. <i>Cancer Letters</i> , 2018, 432, 251-259.	7.2	59
112	Temozolomide combined with irinotecan regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model. <i>Oncotarget</i> , 2018, 9, 7774-7781.	1.8	22
113	Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models. <i>Oncotarget</i> , 2018, 9, 915-923.	1.8	42
114	Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse models. <i>Oncotarget</i> , 2018, 9, 11119-11125.	1.8	35
115	Recombinant methioninase combined with doxorubicin (DOX) regresses a DOX-resistant synovial sarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 19263-19272.	1.8	22
116	Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2018, 9, 37333-37342.	1.8	15
117	Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. , 2018, , .		0
118	Calcium Phosphate Cement in the Surgical Management of Benign Bone Tumors. <i>Anticancer Research</i> , 2018, 38, 3031-3035.	1.1	6
119	Tumor-Targeting <i>Salmonella typhimurium</i> A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2314-2319.	2.6	53
120	High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 2739-2743.	2.6	34
121	Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model. <i>Cell Cycle</i> , 2017, 16, 1063-1069.	2.6	30
122	Analysis of Stroma Labeling During Multiple Passage of a Sarcoma Imageable Patient-Derived Orthotopic Xenograft (iPDOX) in Red Fluorescent Protein Transgenic Nude Mice. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 3367-3371.	2.6	14
123	Intra-arterial administration of tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Cell Cycle</i> , 2017, 16, 1164-1170.	2.6	49
124	Color-coded intravital imaging demonstrates a transforming growth factor- β 2 (TGF- β 2) antagonist selectively targets stromal cells in a human pancreatic-cancer orthotopic mouse model. <i>Cell Cycle</i> , 2017, 16, 1008-1014.	2.6	12
125	<i>Salmonella typhimurium</i> A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide. <i>Cell Cycle</i> , 2017, 16, 1288-1294.	2.6	37
126	Neoadjuvant chemoradiotherapy of pancreatic cancer induces a favorable immunogenic tumor microenvironment associated with increased major histocompatibility complex class II-related chain A/B expression. <i>Journal of Surgical Oncology</i> , 2017, 116, 416-426.	1.7	28

#	ARTICLE	IF	CITATIONS
127	The irony of highly-effective bacterial therapy of a patient-derived orthotopic xenograft (PDOX) model of Ewing's sarcoma, which was blocked by Ewing himself 80 years ago. <i>Cell Cycle</i> , 2017, 16, 1046-1052.	2.6	38
128	MZB1 in borderline resectable pancreatic cancer resected after neoadjuvant chemoradiotherapy. <i>Journal of Surgical Research</i> , 2017, 220, 391-401.	1.6	17
129	Patient-derived orthotopic xenograft (PDOX) mouse model of adult rhabdomyosarcoma invades and recurs after resection in contrast to the subcutaneous ectopic model. <i>Cell Cycle</i> , 2017, 16, 91-94.	2.6	41
130	Labeling the Stroma of a Patient-Derived Orthotopic Xenograft (PDOX) Mouse Model of Undifferentiated Pleomorphic Soft-Tissue Sarcoma With Red Fluorescent Protein for Rapid Non-Invasive Imaging for Drug Screening. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 361-365.	2.6	34
131	Near-Infrared Tumor-Specific Fluorescence Imaging of Pancreatic Cancer in Orthotopic Mouse Models Using the Da-Vinci Firefly Imaging System. <i>Journal of the American College of Surgeons</i> , 2017, 225, S194-S195.	0.5	1
132	High-efficacy targeting of colon-cancer liver metastasis with <i>Salmonella typhimurium</i> A1-R via intra-portal-vein injection in orthotopic nude-mouse models. <i>Oncotarget</i> , 2017, 8, 19065-19073.	1.8	11
133	Tumor-targeting <i>Salmonella typhimurium</i> A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug. <i>Oncotarget</i> , 2017, 8, 8035-8042.	1.8	50
134	Clinical Factors That Affect the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts: A University of California, Los Angeles, Sarcoma Program Prospective Clinical Trial. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	3.0	5
135	Abstract 5900: Transforming growth factor-beta (TGF- β) inhibitor modulates cancer stroma in a pancreatic cancer orthotopic mouse model. , 2017, , .		1
136	Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 35630-35638.	1.8	77
137	Temozolomide combined with irinotecan caused regression in an adult pleomorphic rhabdomyosarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2017, 8, 75874-75880.	1.8	33
138	MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 47490-47496.	1.8	37
139	A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatin and doxorubicin in a patient-derived orthotopic xenograft (PDOX). <i>Oncotarget</i> , 2017, 8, 63353-63359.	1.8	24
140	A patient-derived orthotopic xenograft (PDOX) mouse model of a cisplatin-resistant osteosarcoma lung metastasis that was sensitive to temozolomide and trabectedin: implications for precision oncology. <i>Oncotarget</i> , 2017, 8, 62111-62119.	1.8	48
141	Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2017, 8, 85516-85525.	1.8	67
142	The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and <i>CDKN2A</i> deletion: Direction for third-line patient therapy. <i>Oncotarget</i> , 2017, 8, 103129-103136.	1.8	38
143	Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) is Sensitive to Cisplatin and Resistant to Nab-paclitaxel. <i>Anticancer Research</i> , 2017, 37, 61-66.	1.1	20
144	Precision medicine for recalcitrant cancers with the patient-derived orthotopic xenograft (PDOX) mouse models for identification of effective therapy. <i>Journal of Clinical Oncology</i> , 2017, 35, e23164-e23164.	1.6	0

#	ARTICLE	IF	CITATIONS
145	Effective Metabolic Targeting of Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models with Recombinant Methioninase. <i>Anticancer Research</i> , 2017, 37, 4807-4812.	1.1	16
146	Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model. <i>Oncotarget</i> , 2016, 7, 71737-71743.	1.8	72
147	The outcomes of reconstruction using frozen autograft combined with iodine-coated implants for malignant bone tumors: compared with non-coated implants. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 735-740.	1.3	12
148	Utilization of Distilled Water Lavage for Localized Fluid Collection After Combined Hepatectomy and Cyst Fenestration for Polycystic Liver Disease. <i>International Surgery</i> , 2016, 101, 535-541.	0.1	0
149	Efficacy of glycogen synthase kinase-3 β targeting against osteosarcoma via activation of β -catenin. <i>Oncotarget</i> , 2016, 7, 77038-77051.	1.8	23
150	Tumor-targeting <i>Salmonella typhimurium</i> A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model. <i>Oncotarget</i> , 2016, 7, 85929-85936.	1.8	77
151	High efficacy of tumor-targeting <i>Salmonella typhimurium</i> A1-R on a doxorubicin- and dactolisib-resistant follicular dendritic-cell sarcoma in a patient-derived orthotopic xenograft PDOX nude mouse model. <i>Oncotarget</i> , 2016, 7, 33046-33054.	1.8	93
152	Effective molecular targeting of CDK4/6 and IGF-1R in a rare <i>FUS-ERG</i> fusion <i>CDKN2A</i> -deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model. <i>Oncotarget</i> , 2016, 7, 47556-47564.	1.8	91
153	Non-toxic Efficacy of the Combination of Caffeine and Valproic Acid on Human Osteosarcoma Cells In Vitro and in Orthotopic Nude-mouse Models. <i>Anticancer Research</i> , 2016, 36, 4477-4482.	1.1	7
154	Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 15, 390-399.	1.7	11
155	Late Recurrence of Osteosarcoma: A Report of Two Cases. <i>Journal of Orthopaedic Surgery</i> , 2014, 22, 415-419.	1.0	3
156	Detection of <i>MDM2</i> gene amplification in soft tissue sarcoma by FISH.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10562-10562.	1.6	5
157	Prognostic value of novel combined scoring system in patients with high-grade soft tissue sarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, e21523-e21523.	1.6	0
158	Dendritic cells immunotherapy for patients with malignant bone and soft tissue tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10539-10539.	1.6	0
159	Impact of excision repair cross-complementation group 1 (ERCC1) protein on survival of patients with osteosarcoma treated with cisplatin-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10535-10535.	1.6	0
160	Prognostic value of peroxisome proliferator-activated receptor gamma expression on clinical outcome of myxoid liposarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10574-10574.	1.6	0
161	Efficacy of novel proteasome inhibitory platinum complex against osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 10534-10534.	1.6	0
162	Long-term outcomes of tumor-bearing autografts treated with liquid nitrogen for reconstruction after tumor removal.. <i>Journal of Clinical Oncology</i> , 2014, 32, e21508-e21508.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Pelvic reconstruction for malignant bone tumors using recycled frozen autograft.. Journal of Clinical Oncology, 2014, 32, e21505-e21505.	1.6	0
164	Prognostic Value of Histological Response to Chemotherapy in Osteosarcoma Patients Receiving Tumor-Bearing Frozen Autograft. PLoS ONE, 2013, 8, e71362.	2.5	27
165	Efficacy of newly developed platinum complexes against osteosarcoma, bone-targeting platinum, and proteasome inhibitory platinum.. Journal of Clinical Oncology, 2012, 30, 10075-10075.	1.6	0
166	Marginal resection for osteosarcoma: Long-term outcomes.. Journal of Clinical Oncology, 2012, 30, e20505-e20505.	1.6	0